文献速递胃肠动力与功能性疾病

促动力药对胃排空和症状的影响:系统评价与Meta分析

Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.
PubMed 文献 · Gastroenterology · 2019-01-31

该系统评价与Meta分析检索了Ovid MEDLINE、EMBASE和Cochrane对照试验中心注册库,纳入22项评估胃排空变化、23项评估上消化道症状、14项同时评估两者的随机盲法平行或交叉试验,涉及功能性消化不良和胃轻瘫患者。促动力药显著加速胃排空(T1/2平均缩短16.3分钟,95%CI -22.1至-10.6分钟),并显著减轻上消化道症状(平均减少0.25个标准差,95%CI -0.37至-0.13个标准差)。Meta回归显示胃排空变化与症状改善无显著关联,但在采用最佳胃排空检测方法的研究中两者呈显著正相关(P = .02)。

要点

  • 促动力药显著加速胃排空,T1/2平均缩短16.3分钟(95%CI -22.1至-10.6分钟)。
  • 促动力药显著减轻上消化道症状,平均减少0.25个标准差(95%CI -0.37至-0.13个标准差)。
  • 仅采用最佳胃排空检测方法时,胃排空改善与症状改善呈显著正相关(P = .02)。

核心结论

  • 促动力药可显著加速胃排空(采用最佳检测方法时)并显著改善上消化道症状。
  • 胃排空变化与症状改善的整体关联不显著,但仅纳入最佳胃排空检测方法的研究时两者呈显著正相关(P = .02)。

研究设计与样本

  • 由专家图书馆员对Ovid MEDLINE(1946年至今)、EMBASE(1988年至2018年1月)和EBM Reviews Cochrane对照试验中心注册库进行广泛检索,不限语言和年份。
  • 两名独立评价者按纳入标准筛选:5HT4激动剂、D2受体拮抗剂或胃饥饿素激动剂的随机盲法平行或交叉试验;测量胃排空(T1/2)变化或上消化道复合症状的试验;功能性消化不良和胃轻瘫患者的试验;以及胃排空检测方法的试验。
  • 共考虑899项研究,其中22项评估胃排空变化,23项评估上消化道症状,14项同时评估胃排空和上消化道症状。
  • 采用标准化均数差(单位以标准差表示)标准化症状评估,使用随机效应模型分析数据,并用Meta回归评估胃排空变化与上消化道症状的关联。

主要发现

  • 促动力药在所有研究中显著加速胃排空(T1/2平均缩短16.3分钟,95%CI -22.1至-10.6分钟)。
  • 在采用最佳胃排空检测方法的研究中,促动力药显著加速胃排空(T1/2平均缩短23.6分钟,95%CI -32.3至-14.9分钟)。
  • 促动力药显著减轻上消化道症状(平均减少0.25个标准差,95%CI -0.37至-0.13个标准差)。
  • Meta回归显示胃排空变化与上消化道症状之间无显著关联。
  • 仅评估采用最佳胃排空检测方法的研究时,胃排空改善与上消化道症状改善呈显著正相关(P = .02)。

关键数值与推荐

  • 最佳或中等胃排空检测方法定义为:闪烁扫描法或呼气试验、固体餐、持续时间超过2小时。
  • 促动力药在所有研究中T1/2平均缩短16.3分钟(95%CI -22.1至-10.6分钟)。
  • 促动力药在采用最佳胃排空检测方法的研究中T1/2平均缩短23.6分钟(95%CI -32.3至-14.9分钟)。
  • 促动力药使上消化道症状平均减少0.25个标准差(95%CI -0.37至-0.13个标准差)。
  • 仅采用最佳胃排空检测方法时,胃排空改善与上消化道症状改善的关联P = .02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Studies have reported a lack of association between improvements in gastric emptying (GE) and upper gastrointestinal (UGI) symptoms with promotility drugs. However, GE test methods were suboptimal in some studies. We assessed improvements in GE and UGI symptoms in patients given promotility agents in studies with optimal or moderate test methods (scintigraphy or breath test, solid meal, >2 hours duration) compared to studies with suboptimal GE test methods. METHODS: With an expert librarian, we completed an extensive search of publications in the Ovid MEDLINE (1946 to present), EMBASE (1988 to January 2018), and EBM Reviews Cochrane Central Register of Controlled Trials, without restrictions on language or year. Two independent reviewers evaluated the following inclusion criteria: randomized, blinded, parallel, or crossover trials of 5HT4 agonists, D2 receptor antagonist, or ghrelin agonists; trials that measured change in GE (T1/2) or composite UGI symptoms; trials of patients with functional dyspepsia and gastroparesis; and trials of GE test methods. Standardized mean differences (units expressed as SD) were used to standardize symptom assessments that were not uniform across studies. Random effects model was used to analyze data and meta-regression was used to evaluate the association between change in GE and UGI symptoms. RESULTS: Of 899 studies considered, 22 studies assessed change in GE; 23 evaluated UGI symptoms; and 14 evaluated GE and UGI symptoms. Promotility agents significantly accelerated GE (T1/2) in all studies (mean reduction in T1/2, 16.3 minutes; 95% confidence interval, -22.1 to -10.6 minutes) and in studies that used optimal GE test methods (mean reduction in T1/2, 23.6 minutes; 95% confidence interval, -32.3 to -14.9 minutes). Promotility agents also significantly reduced UGI symptoms (mean reduction, 0.25 SD; 95% confidence interval, -0.37 to -0.13 SD). Meta-regression found no significant association between change in GE and UGI symptoms. However, when only studies with optimal GE test methods were evaluated, there was a significant positive association between improvement in GE and UGI symptoms (P = .02). CONCLUSIONS: In a meta-analysis of published trials, we found promotility agents to significantly accelerate GE (when optimal test methods were used) and to produce significant improvements in UGI symptoms.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Vijayvargiya P, Camilleri M, Chedid V, et al. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis. Gastroenterology. 2019. PMID: 30711628. doi:10.1053/j.gastro.2019.01.249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。